This content is restricted.
Brief
On 03/02/2025, the Medicines and Healthcare products Regulatory Agency (MHRA) issued an update regarding MHRA asks for views on proposed guidance to support the safe regulation of new personalised cancer therapies. The agency launched a consultation on regulatory guidance for individualised mRNA cancer immunotherapies, seeking comments from stakeholders and the public on draft guidance that addresses unique scientific questions on how these treatments should be regulated.
Highlights content goes here...
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested
